Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

Cancer Biology and Medicine

Volumn 13, Issue 2, 2016, Pages 157-170

  Mino Kenudson, Mari ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Immunohistochemistry; PD 1; PD L1; Predictive

Indexed keywords

BIOLOGICAL MARKER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; ETHNICITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW;

EID: 84978786133     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.20892/j.issn.2095-3941.2016.0009     Document Type: Review

References (61)

1. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2014; 32: 129-60.
2. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-Small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015; 13: 515-24.
3. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba 2, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998-2006.
4. Baxevanis CN, Perez SA. Cancer dormancy: a regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state. Vaccines (Basel). 2015; 3: 597-619.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-64.
6. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372: 2018-28.
7. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-7.
8. Topalian SL, Hodi FS, Brahmer JR, Smith DC, Mcdermott DF, Carvajal RD, et al. Safety, activity, and immune correlates of Anti- PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-54.
9. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123-35.
10. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous nonsmall- cell lung cancer. N Engl J Med. 2015; 373: 1627-39.
11. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015 Dec 18. p2: S0140-6736(15)01281-7. [Epub ahead of print]
12. Spira AI, Park K, Mazieres J, Vansteenkiste JF, Rittmeyer A, Ballinger M, et al. Efficacy, safety and predictive biomarker results from a randomized phase 2 study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin oncol. 2015; 33 (suppl): abstr 8010.
13. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007; 13: 84-8.
14. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105: 20852-7.
15. Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in Non-Small cell lung cancer. Clin Cancer Res. 2015; 21: 4014-21.
16. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3: 1355-63.
17. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015; 10: 910-23.
18. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015; 6: 14209-19.
19. Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol. 2015; 28: 1154-66.
20. Lin C, Chen X, Li M, Liu J, Qi X, Yang W, et al. Programmed Death-Ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor Mutation-Positive lung adenocarcinoma. Clin Lung Cancer. 2015; 16: e25-35.
21. Zhang Y, Wang L, Li Y, Pan YJ, Wang R, Hu HC, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014; 7: 567-73.
22. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015; 5: 915-9.
23. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007; 30: 251-60.
24. Lee SJ, Jang BC, Lee SW, Yang Y, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274) FEBS Lett. 2006; 580: 755-62.
25. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20: 5064-74.
26. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova TA, Fitz LJ, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192: 1027-34.
27. Taube JM, Anders RA, Young GD, Xu H, Sharma R, Mcmiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra37.
28. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515: 568-71.
29. Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, et al. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in Non-Small cell lung cancer. J Thorac Oncol. 2016; 11: 62-71.
30. Zhu JJ, Chen LX, Zou LT, Yang PP, Wu RR, Mao Y, et al. MiR-20b, -21, and-130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014; 75: 348-53.
31. Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, et al. The clinical relevance of the miR-197/CKS1B/STAT3- mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther. 2015; 23: 717-27.
32. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5: 5241.
33. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014; 74: 665-74.
34. Noman MZ, Desantis G, Janji BA, Karray S, Dessen P, Bronte V, et al. PD-L1 is a novel direct target of HIF-1 alpha., and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211: 781-90.
35. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014; 25: 1935-40.
36. Boland JM, Kwon ED, Harrington SM, Tang H, Yang P, Aubry MC. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer. 2013; 14: 157-63.
37. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS mutant lung cancer. J Thorac Oncol. 2015;10:1726-35.
38. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012; 98: 751-5.
39. Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP, Yin YL, et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J. 2013; 28: 147-51.
40. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015; 89: 181-8.
41. D'incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015; 112: 95-102.
42. Kim MY, Koh J, Kim S, Go HA, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015; 88: 24-33.
43. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004; 10: 5094-100.
44. Mao YX, Li W, Chen K, Xie YF, Liu Q, Yao M, et al. B7-H1 and B7-H3 are Independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6: 3452-61.
45. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer May contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011; 28: 682-8.
46. Velcheti V, Schalper KA, Carvajal DE, Syrigos KN, Sznol MA, Gettinger SN, et al. Programmed death ligand-1 expression in nonsmall cell lung cancer. Lab Invest. 2014; 94: 107-16.
47. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014; 50: 1361-9.
48. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a metaanalysis. J Thorac Dis. 2015; 7: 462-70.
49. Huynh T, Oyarvide VM, Uruga H, Bozkurtlar E, Gainor JF, Hata AN, et al. Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression. J Clin Oncol. 2015; 33 (supple): abstr 7555.
50. Harbison CT, Kurland JF, Horak CE, Cogswell JP, Inzunza HD, Hu X, et al. Characterization of PD-L1 expression and assessment of association with tumor histology and gene expression status in pretreatment non-small cell lung cancer (NSCLC) tumor specimens. J Thorac Oncol. 2014; 9 (Supplement 9): S7-S52.
51. Zhong A, Xing Y, Pan X, Shi M, Xu H. Prognostic value of programmed cell death-ligand 1 expression in patients with nonsmall- cell lung cancer: evidence from an updated meta-analysis. Onco Targets Ther. 2015; 8: 3595-601.
52. Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu WJ, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:suppl; abstr 8032.
53. Hato SV, Khong A, De Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014; 20: 2831-7.
54. Bozkurtlar E, Uruga H, Huynh T, Lanuti M, Mark E, Mino-Kenudson M. Comparison of programmed cell death ligand 1 (PDL1) expression in main tumor and lymph node metastasis of stage 2 and 3 lung adenocarcinomas. Mod Pathol. 2015; 28: 474A.
55. Tokito T, Azuma K, Kawahara A, Ish2 H, Yamada K, Matsuo N, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage 3 non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016; 55: 7-14.
56. Teixido C, Karachaliou N, Gonzalez-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med. 2015; 12: 87-95.
57. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016; 2: 46-54.
58. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016; 27: 147-53.
59. Kim J, Sorensen SF, Choi Y-L, Wang Z, Sun JM, Chio H, et al. PDL1 expression in paired nonsmall cell lung cancer tumor samples. Cancer Res. 2015;75 (15 suppl): abstr 570.
60. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-8.
61. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu WJ, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature. J Clin Oncol. 2015; 33(suppl): abstr 3001.